Verici Dx plc (LON:VRCI – Get Free Report) shares were up 14.3% on Friday . The stock traded as high as GBX 0.40 and last traded at GBX 0.40. 832,000 shares changed hands during mid-day trading, a decline of 51% from the average daily volume of 1,684,113 shares. The stock had previously closed at GBX 0.35.
Verici Dx Stock Performance
The firm’s 50 day moving average price is GBX 0.40 and its 200-day moving average price is GBX 0.54. The firm has a market cap of £11.95 million, a price-to-earnings ratio of -0.44 and a beta of 1.26. The company has a debt-to-equity ratio of 3.03, a current ratio of 3.94 and a quick ratio of 8.49.
Verici Dx Company Profile
Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.
Featured Articles
- Five stocks we like better than Verici Dx
- AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target
- Micron’s $250 Billion Bet Could Reshape the AI Memory Race
- Rocket Lab’s Stock Drop Comes With a Bullish Twist
- Amazon’s New Debt Deal Puts Its AI Spending Story on Trial
Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.
